Both significant and advanced NAFLD fibrosis patients had far more FSTL3-positive area shown by AOD [0.37 (0.32, 0.41) vs 0.09 (0.07, 0.15), p < 0.001] than patients with F0 and F1 fibrosis. The gene discussed is FSTL3; the disease is metabolic dysfunction-associated steatotic liver disease.